-

Charles River Laboratories to Present at Baird and Morgan Stanley Conferences

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at two upcoming investor conferences, including:

  • Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9th, at 10:00 a.m. EDT; and
  • Baird 2025 Global Healthcare Conference on Wednesday, September 10th, at 9:40 a.m. EDT.

Management will present an overview of Charles River’s strategic focus, business developments, and recent trends.

A live webcast of each presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website after each presentation and will remain available for at least two weeks.

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

Contacts

Investor Relations Contact:
Todd Spencer
Corporate Vice President, Investor Relations
781.222.6455
todd.spencer@crl.com

Charles River Laboratories International, Inc.

NYSE:CRL

Release Summary
Charles River Laboratories to Present at Baird and Morgan Stanley Conferences
Release Versions

Contacts

Investor Relations Contact:
Todd Spencer
Corporate Vice President, Investor Relations
781.222.6455
todd.spencer@crl.com

More News From Charles River Laboratories International, Inc.

Charles River Collaborates with Magellan Stem Cells to Advance Stem Cell and Regenerative Medicine Development

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and Magellan Stem Cells, a private Australian biotech and cell-therapy firm, announce their collaboration to support Magellan in the development and clinical advancement of its proprietary stem cell-based therapies and regenerative medicine solutions. The partnership will leverage Charles River’s specialized expertise in biologics quality control, current Good Manufacturing Practice (cGMP) viral and r...

Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call...

Charles River and Autolomous Partner to Transform Laboratory Execution Systems

WILMINGTON, Mass. & LONDON--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and Autolomous today announced the launch of Apollo Orchestrate™, a new capability within Charles River's Apollo® platform that connects and digitizes laboratory execution, built on Autolomous's autoloMATE® digital Laboratory Execution System (LES). The launch demonstrates continued progress on Charles River's strategic commitment to modernize and digitize laboratory workflows. Apollo® Orches...
Back to Newsroom